What changed
$SNY — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.1B | EPS $1.10 vs $1.03 🟢
💡 Consensus prices in low single-digit EPS growth and a static ~10x P/E; our variant view is that mid-to-high single-digit EPS growth and re-rating to 11-12x P/E is achievable as the market recognizes pipeline optionality and Dupixent's durability, creating a ~20% upside gap.
📉 Reward/risk: 2.5:1
🏢 Business Quality: 8/10 - Best-in-class immunology franchise (Dupixent), diversified vaccines and rare disease portfolio, strong cash flows, and a deep late-stage pipeline.
📊 Valuation: cheap - Trailing P/E 9.7x vs. pharma peers 14x, EV/EBITDA ~7x vs. sector 12x, FCF yield 7.5%; reverse DCF implies minimal growth priced in, intrinsic...
🔮 Catalyst: Q4 earnings beat with upward guidance revisions, upcoming tolebrutinib US filing and Dupixent label expansions.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SNY0618